Drugs / Satoreotide tetraxetan
Satoreotide tetraxetan
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03773133 | May → Oct 2019 | small cell lung carcinoma | Ipsen | Terminated | No outcome recorded |
| Phase 1/2 | NCT02592707 | Mar 2017 → Feb 2022 | neuroendocrine neoplasm | Ipsen | Terminated | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Satoreotide tetraxetan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02592707 ↗ |
| Known as | Dota satoreotide | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297531 ↗ |
| Known as | DOTA-JR-11 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297531 ↗ |
| Known as | Satoreotida tetraxetan | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297531 ↗ |
| Known as | Satoreotide dota | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297531 ↗ |
| Action | Inhibit | “PURPOSE: We present the results of an open-label, phase I/II study evaluating the safety and efficacy of the novel somatostatin receptor (SSTR) antagonist [177Lu]Lu-satoreotide...” PMID 37721581 ↗ Sep 2023 |
| Modality | Protein / enzyme biologic | — CHEMBL4297531 ↗ |
| Route | Intravenous | “following fractionated i.v. administrations” NCT03773133 ↗ |